EUVIMEDEUVIMED entdecken
Crossref

Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen

Akihito Shinohara iD, Michiho Shindo, Nobuaki Nakano, Emiko Sakaida, Naoyuki Uchida, Kentaro Fukushima, Hideyuki Nakazawa iD, Kentaro Serizawa, Yoshinobu Kanda, Toshiro Kawakita, Takashi Ikeda, Hiroyuki Ohigashi und 7 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Akihito Shinohara und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Hematologic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fludarabine and myeloablative busulfan (FluBu4) in allogeneic hematopoietic stem cell transplantation (HSCT) for older people have not been adequately examined. This retrospective study analyzed data from a large‐scale, nationwide database in Japan. Adult patients (> 15 years old, y/o) who received their first HSCT with FluBu4 for hematological malignancies were included. They were categorized into the younger (< 60 y/o, N = 1295) and the older group (≥ 60 y/o, N = 993). The 3‐year overall survival (OS) rate after HSCT was significantly worse in the older group than in the other ( p < 0.01, 39.9% vs. 48.5%). The 3‐year non‐relapse mortality (NRM) was significantly higher in the older group than in the other ( p < 0.01, 30.9% vs. 23.0%), and the 3‐year cumulative incidence of relapse was comparable between them. According to the multivariate analysis, age ≥ 60 years was significantly associated with poor OS and high NRM. In a subgroup analysis of the older group, the use of additional chemotherapeutic drugs to FluBu4 was significantly associated with poor OS and high NRM. Total body irradiation was significantly associated with high NRM and 1‐year incidence of sinusoidal obstruction syndrome but not with OS. Thus, FluBu4 should be used with caution in older people.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationTransplantation ConditioningHematologic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansBusulfanMiddle AgedMaleVidarabineFemaleAgedTransplantation, HomologousAdultRetrospective StudiesAge FactorsMyeloablative AgonistsYoung AdultTreatment OutcomeAdolescentJapanGraft vs Host Disease

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantationbusulfanconditioning regimenolder people

Substanzen

BusulfanfludarabineVidarabineMyeloablative Agonists

Autor:innen und Institutionen

  • Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Hematology, Seifukai Clinic, Miyakonojo, Japan.
  • Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
  • Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.

ORCID-Profile: Akihito Shinohara, Hideyuki Nakazawa

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Shinohara, A., Shindo, M., Nakano, N., Sakaida, E., Uchida, N., Fukushima, K., Nakazawa, H., Serizawa, K., Kanda, Y., Kawakita, T., Ikeda, T., Ohigashi, H., Ito, A., Wakayama, T., Matsuoka, K. I., Fukuda, T., Tanaka, J., Atsuta, Y., & Nakasone, H. (2025). Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen. European Journal of Haematology. https://doi.org/10.1111/ejh.14374

Vancouver

Shinohara A, Shindo M, Nakano N, Sakaida E, Uchida N, Fukushima K, et al. Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen. European Journal of Haematology. 2025. doi:10.1111/ejh.14374

BibTeX
@article{Shinohara2025,
  author = {Shinohara, Akihito and Shindo, Michiho and Nakano, Nobuaki and Sakaida, Emiko and Uchida, Naoyuki and Fukushima, Kentaro and Nakazawa, Hideyuki and Serizawa, Kentaro and Kanda, Yoshinobu and Kawakita, Toshiro and Ikeda, Takashi and Ohigashi, Hiroyuki and Ito, Ayumu and Wakayama, Toshio and Matsuoka, Ken-Ichi and Fukuda, Takahiro and Tanaka, Junji and Atsuta, Yoshiko and Nakasone, Hideki},
  title = {Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14374}
}
Kostenlos starten →